Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
Px Wire April-June 2022, Vol. 12, No. 1
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
COMPASS Africa Newsletter (July 2022)
Midterm Newsletter 2022
Developed by the COMPASS MERL team, this issue offers SPARC stories and details on the MERL roadshow.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.
MERL Handbook for Advocacy Champions
Everything you need to know about MERL for effective advocacy
This handbook has been put together from various training materials that have been utilized to build the MERL capacity of partners in the Coalition to build Momentum, Power, Activism, Strategy and Solidarity in Africa (COMPASS); between 2018 and 2021.
The overarching aim of this handbook is to enhance theimpact of campaigns; by empowering you with tools to monitor, evaluate and learn from your advocacy. This is a simple guide to understand advocacy MERL!
Translating Scientific Advance into Public Health Impact
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years of delivering oral PrEP and how to move faster, more strategically, and with greater coordination to maximize the impact of injectable CAB for PrEP.
Statement on the Dapivirine Ring for Women: Call for Accelerated Global Access
This statement, from a coalition of advocates, applauds the WHO for its ongoing support and its 2021 recommendation of the dapivirine vaginal ring as an additional prevention option for women. The advocates call on funders, country governments and community leaders to sustain their support for the ring’s introduction and rollout in African countries where it is needed and for prompt regulatory reviews. And they call on HIV programs to integrate the ring, and collaborate with communities on the design of those programs.
Research Fundamentals: An HIV Vaccine — What’s the challenge and what’s the science?
Some vaccines are easier to develop than others. COVID-19 vaccines were developed with unprecedented speed, taking a matter of months to become available. A measles vaccine took about 10 years to develop. But the field’s been working on an HIV vaccine for 40 years.
In this episode, AVAC’s Jeanne Baron and co-host immunologist Katharine Kripke of AVENIR Health explore why HIV is different with two experts on vaccine research: Caltech’s Pamela Bjorkman and IAVI’s Vincent Kioi.
Learn how HIV has evolved like no other virus today to escape detection by the immune system. Learn why the right target on HIV is so hard to reach and how scientists are tackling it all.
Previous Research Fundamentals
More Vaccine Resources
Time to Develop a Vaccine
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.
Phase 1 mRNA HIV Vaccine Trials
A breakdown of current HIV mRNA trials and a primer on the basics of mRNA technology.